title: Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis.
abstract: OBJECTIVE
  To clarify the mechanism of block of nicotinic receptor channels by myasthenic antibodies.
  
  
  BACKGROUND
  Nicotinic acetylcholine receptor (nAChR) channel currents are functionally blocked by purified immunoglobulin G (IgG) of patients with myasthenia gravis (MG).
  
  
  METHODS
  The molecular mechanism of block of IgG fractions containing antibodies to nAChR channels was tested with the patch-clamp technique in combination with a system for ultrafast solution exchange. For the experiments, outside-out patches from cultured mouse myotubes that express embryonic-type nAChR channels at their surface were used.
  
  
  RESULTS
  Incubation of outside-out patches with purified IgG from four myasthenic patients blocked nAChR channel currents activated by the application of 1.0 mM ACh reversibly. The peak current amplitude and the time course of block of nAChR channels decreased with increasing concentrations of IgG. The block became at least partly irreversible if incubation time of outside-out patches exceeded 2 minutes. For the block of nAChR channel currents with a-bungarotoxin, a similar mechanism of block was found.
  
  
  CONCLUSIONS
  The reversibility of functional block of nAChR channel currents by myasthenic IgG depended strongly on the incubation time of the receptors with antibodies. Interaction of myasthenic antibodies with nicotinic receptors may proceed in several stages from a low-affinity reversible to a high-affinity irreversible binding.
authors.affiliation: Department of Neurology Medizinische Hochschule Hannover, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Jahn
authors.forename: C
authors.initials: C
authors.lastname: Franke
authors.forename: J
authors.initials: J
authors.lastname: Bufler
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000831:Animals, Newborn; D001323:Autoantibodies / Q000097:blood / Q000494:pharmacology*; D002478:Cells, Cultured; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000494:pharmacology*; D015640:Ion Channel Gating / Q000276:immunology*; D008297:Male; D008564:Membrane Potentials / Q000276:immunology; D051379:Mice; D008875:Middle Aged; D018485:Muscle Fibers, Skeletal / Q000737:chemistry / Q000166:cytology; D018482:Muscle, Skeletal / Q000166:cytology; D009157:Myasthenia Gravis / Q000276:immunology*; D018408:Patch-Clamp Techniques; D011978:Receptors, Nicotinic / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D007074:Immunoglobulin G; D011978:Receptors, Nicotinic